Soleil Boughton Sells 2,572 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Key Points

• Soleil Boughton, an insider at Hims & Hers Health, sold 2,572 shares of the company's stock for $132,818.08 on August 11, reducing their ownership by 1.65% to 153,021 shares.
• Hims & Hers Health's stock has recently experienced a drop of 4.2%, bringing the share price down to $47.88, with a trading volume of over 30 million shares.
• The company's latest quarterly earnings report showed an earnings per share of $0.17, missing expectations and reflecting a year-over-year revenue growth of 72.6% at $544.83 million.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 2,572 shares of Hims & Hers Health stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $51.64, for a total value of $132,818.08. Following the sale, the insider directly owned 153,021 shares in the company, valued at approximately $7,902,004.44. This trade represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Monday, July 28th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The stock was sold at an average price of $58.70, for a total value of $150,976.40.
• On Monday, July 14th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The stock was sold at an average price of $47.82, for a total value of $122,993.04.
• On Monday, June 30th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The shares were sold at an average price of $50.50, for a total value of $129,886.00.
• On Tuesday, June 17th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The shares were sold at an average price of $59.75, for a total value of $153,677.00.
• On Monday, June 16th, Soleil Boughton sold 5,451 shares of Hims & Hers Health stock. The shares were sold at an average price of $56.80, for a total value of $309,616.80.
• On Tuesday, May 27th, Soleil Boughton sold 3,233 shares of Hims & Hers Health stock. The shares were sold at an average price of $55.87, for a total value of $180,627.71.

Hims & Hers Health Trading Down 4.2%

HIMS stock traded down $2.10 during trading on Tuesday, hitting $47.88. The company had a trading volume of 30,015,931 shares, compared to its average volume of 34,277,801. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The firm has a 50-day moving average price of $53.53 and a 200-day moving average price of $45.29. Hims & Hers Health, Inc. has a 12 month low of $13.47 and a 12 month high of $72.98. The stock has a market cap of $10.72 billion, a price-to-earnings ratio of 59.85, a PEG ratio of 3.29 and a beta of 2.08.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%. The company had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. During the same quarter last year, the firm earned $0.06 EPS. The business's revenue for the quarter was up 72.6% on a year-over-year basis. As a group, analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on HIMS. Needham & Company LLC reaffirmed a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Piper Sandler reaffirmed a "neutral" rating and set a $39.00 price objective (up from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. UBS Group set a $30.00 target price on Hims & Hers Health in a report on Monday, June 23rd. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Finally, Morgan Stanley reissued an "equal weight" rating and issued a $40.00 target price on shares of Hims & Hers Health in a report on Wednesday, June 11th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $39.83.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. LPL Financial LLC raised its position in shares of Hims & Hers Health by 1.0% during the 4th quarter. LPL Financial LLC now owns 97,958 shares of the company's stock valued at $2,369,000 after acquiring an additional 980 shares during the last quarter. O Shaughnessy Asset Management LLC bought a new stake in shares of Hims & Hers Health during the 4th quarter valued at $208,000. Envestnet Asset Management Inc. raised its position in shares of Hims & Hers Health by 139.2% during the 4th quarter. Envestnet Asset Management Inc. now owns 78,686 shares of the company's stock valued at $1,903,000 after acquiring an additional 45,791 shares during the last quarter. Invesco Ltd. raised its position in shares of Hims & Hers Health by 613.9% during the 4th quarter. Invesco Ltd. now owns 1,277,026 shares of the company's stock valued at $30,878,000 after acquiring an additional 1,098,148 shares during the last quarter. Finally, Legal & General Group Plc raised its position in shares of Hims & Hers Health by 209.3% during the 4th quarter. Legal & General Group Plc now owns 572,263 shares of the company's stock valued at $13,841,000 after acquiring an additional 387,225 shares during the last quarter. Institutional investors own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.